Target cell-restricted triggering of the CD95 (APO-1/Fas) death receptor with bispecific antibody fragments

• Verfasst von: Jung, Gundram [VerfasserIn]
• Verfasst von: Krammer, Peter H. [VerfasserIn]
• Titel: Target cell-restricted triggering of the CD95 (APO-1/Fas) death receptor with bispecific antibody fragments
• Verf.angabe: Gundram Jung, Ludger Grosse-Hovest, Peter H. Krammer, and Hans-Georg Rammensee
• E-Jahr: 2001
• Jahr: March 1, 2001
• Umfang: 4 S.
• Teil: volume:61
• Teil: year:2001
• Teil: number:5
• Teil: pages:1846-1848
• Teil: extent:4
• Fussnoten: Gesehen am 26.04.2021
• Titel Quelle: Enthalten in: Cancer research
• Ort Quelle: Philadelphia, Pa. : AACR, 1916
• Jahr Quelle: 2001
• Band/Heft Quelle: 61(2001), 5, Seite 1846-1848
• ISSN Quelle: 1538-7445
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1755928513

Abstract

<p>Like many other cell surface receptors, the CD95 (APO-1/Fas) molecule needs to be cross-linked by its physiological ligand or by immobilized or multimeric antibodies to mediate biological activity, that is, induction of apoptotic cell death. Monomeric CD95 antibodies of the IgG2a or IgG1 subtype block rather than induce apoptosis. We report here that such antibodies, hybridized to a second antibody directed against a different target antigen on the same cell, effectively induce apoptosis of the cells if the expression of the target antigen exceeds a certain threshold level. It appears that this effect is due to bicellular binding of bispecific antibodies resulting in mutual cross-linking of the CD95 death receptor and the target antigen. Using bispecific reagents, it may therefore be possible to restrict the activation of death receptors to a given target site, <i>e.g.</i>, a tumor. In general terms, our findings illustrate a principle according to which the triggering of a cell surface receptor may be confined to a given target cell using bispecific reagents with target X cell surface receptor specificity.</p>